Aytu Biopharma, Inc.
AYTU
$2.39
$0.0954.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.88% | -28.03% | -30.99% | -36.16% | -21.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.88% | -28.03% | -30.99% | -36.16% | -21.89% |
| Cost of Revenue | -15.13% | -38.78% | -50.62% | -56.02% | -42.70% |
| Gross Profit | -14.77% | -22.36% | -19.55% | -24.00% | -7.13% |
| SG&A Expenses | -12.39% | -26.03% | -35.31% | -37.68% | -36.38% |
| Depreciation & Amortization | 2.73% | -4.01% | -10.03% | -15.10% | -19.10% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.20% | -28.40% | -39.07% | -42.84% | -39.55% |
| Operating Income | -70.60% | 36.35% | 107.35% | 101.03% | 115.41% |
| Income Before Tax | 117.25% | 75.79% | 88.28% | 31.01% | 66.44% |
| Income Tax Expenses | -46.58% | 71.54% | -- | -- | -- |
| Earnings from Continuing Operations | 109.32% | 68.83% | 78.20% | 19.31% | 62.20% |
| Earnings from Discontinued Operations | 126.76% | 93.61% | -63.37% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 111.98% | 70.87% | 74.46% | 7.08% | 55.40% |
| EBIT | -70.60% | 36.35% | 107.35% | 101.03% | 115.41% |
| EBITDA | -35.33% | -4.57% | 336.75% | 305.98% | 171.90% |
| EPS Basic | 107.62% | 75.98% | 81.48% | 42.19% | 80.20% |
| Normalized Basic EPS | 195.45% | 111.96% | 107.56% | 61.58% | 83.71% |
| EPS Diluted | 60.74% | 56.43% | 74.94% | 42.15% | 80.18% |
| Normalized Diluted EPS | 168.65% | 105.63% | 104.92% | 61.58% | 83.71% |
| Average Basic Shares Outstanding | 15.85% | 23.76% | 38.12% | 64.11% | 85.40% |
| Average Diluted Shares Outstanding | 51.90% | 52.29% | 56.53% | 64.11% | 85.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |